Peripheral T-Cell Lymphoma Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
See the next evidence inflection points before they arrive. This readout-outlook report connects Clinical Trials, Drug & Asset, and Company & Deal Intelligence data through PatSnap MCP Servers. Explore the PatSnap MCP Marketplace to monitor the same endpoint, sponsor and timing signals inside your own AI workflow.
MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. This is strategic research, not medical advice. Trial status, endpoints and timing can change; confirm the underlying records before making decisions.
Readout outlook: why this landscape matters now
Peripheral T-Cell Lymphoma remains an active clinical development field. The competitive center of gravity is moving toward biomarker-defined populations, rational combinations, earlier treatment lines and evidence that can survive active-comparator scrutiny. The PatSnap evidence set used here contains 245 matched trial records and 383 indexed result records before the decision-focused sample below was selected. This companion outlook shifts the decision lens from market breadth to evidence timing: which endpoints can change practice, which sponsors can execute across geographies, and where the next readout may still leave uncertainty.
MCP workflow for a readout-focused landscape
The analysis starts with Clinical Trials MCP and clinical_trial_fetch to align phase, recruitment status, sponsor, countries, primary endpoints and completion dates. clinical_trial_result_fetch then separates already indexed evidence from future catalysts. Drug & Asset drug_fetch adds mechanism and global development status; Company & Deal Intelligence organization_fetch adds sponsor context. Use PatSnap MCP Servers to keep each layer traceable instead of inferring asset or company facts from trial titles.
Trial, endpoint and expected-readout map
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07691450 | Fludeoxyglucose F-18 + Pralatrexate + Belinostat | Phase 1; Not yet recruiting | City of Hope National Medical Center | United States | Occurrence of dose-limiting toxicities (DLT) (Arm A) (Prior to cycle 2 day 1 (cycle length = 28 days)); Occurrence of DLT (Arm B) (Prior to cycle 2 day 1 (cycle length = 21 days)) | 2029-11-24 |
| NCT07676175 | Cyclophosphamide + Prednisone + Doxorubicin Hydrochloride | Phase 2; Not yet recruiting | BeBetter Med, Inc. | China | Overall Response Rate (ORR) (Up to 24 months) | 2028-01-31 |
| NCT07657572 | Intervention not normalized | Not Applicable; Not yet recruiting | Ruijin Hospital | Geography not listed | Progression-free survival (Baseline up to data cut-off (up to approximately 4 years)) | 2029-12-01 |
| NCT07639879 | TR115 | Phase 3; Not yet recruiting | Tarapeutics Science Inc | China | Progression-Free Survival (PFS) (From randomization to disease progression or death from any cause, whichever…) | 2029-07-30 |
Read the table horizontally. Phase shows nominal maturity, but endpoint choice shows what the study can actually prove; geography signals operational breadth; and expected timing reveals whether a program is a near-term catalyst or a long-duration strategic bet.
Readout signals already on record
- A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma (Phase 1/2): the indexed record reports Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A = 0 Participants; Number of Participants With Dose-Limiting Toxicities (DLTs) - Part A = 0 Participants; -.
- A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL) (Phase 2): the indexed record reports -; Overall Response Rate (ORR) by Independent Review Facility (IRF) Assessment Per Revised Response Criteria for Malignant Lymphoma = 96.2 percentage of participants (95% Confidence Interval, 86.8 - 99.5); -.
- First-in-human dual-epitope nanobody anti-CD5 CAR-T for relapsed/refractory T-ALL/PTCL: Phase I dose-escalation and expansion results from the CONQUER trial. (Phase 1): the indexed record reports RP2D = 2.0 ×10^6 CAR-T cells/kg.
These signals are anchors, not league tables. Differences in population, prior treatment, baseline risk, estimand, endpoint definition and follow-up can overwhelm apparent numerical comparisons. The useful question is which uncertainty each result resolves before the next catalyst.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
How assets and sponsors shape readout probability
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Fludeoxyglucose F-18 (Approved), Pralatrexate (Approved; DHFR), Belinostat (Approved; HDACs), Cyclophosphamide (Approved; DNA), Prednisone (Approved; GR). Company & Deal Intelligence records identify sponsor context for City of Hope National Medical Center, BeBetter Med, Inc. (688759), Ruijin Hospital, Tarapeutics Science Inc. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Evidence white space before the next readout cycle
- Prospective biomarker thresholds that predict benefit rather than simply confirm target presence.
- Randomized sequencing evidence after prior targeted therapy, immunotherapy or antibody–drug conjugates.
- Endpoints that connect response depth with durability, quality of life and overall survival.
- Geographically broader development programs with harmonized molecular testing.
Readout-risk implications
A crowded field does not guarantee a crowded evidence set. Programs can still differentiate through an active comparator, a clinically meaningful endpoint, a biomarker-defined responder group, broader geography, or a credible sequencing plan. Sponsors should pressure-test whether the planned readout will close a decision gap; BD teams should distinguish mechanism novelty from evidence novelty; investors should track endpoint maturity and execution risk alongside phase.
Readout watchlist
Monitor recruitment changes, protocol amendments, primary-completion dates, new result indexing, sponsor ownership and multinational expansion. Re-run the MCP workflow as a delta analysis. A change from surrogate to clinical outcome, a delayed completion date, a new active comparator or a scaled partner can materially alter the probability and strategic meaning of the next readout.
Bottom line
Peripheral T-Cell Lymphoma has multiple clinical catalysts, but their value depends on endpoint quality, execution and context. A readout outlook is most useful when it joins trial design, indexed results, asset mechanism and sponsor capacity in one traceable view.
Build your own readout monitor: Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable components for catalyst tracking and SEO-ready reports.
